Skip to main content

Human Papillomavirus: Vaccination

Question for Department of Health

UIN HL1165, tabled on 7 July 2015

To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 16 June (HL229), which indicated that 2,589 serious suspected adverse drug reactions to human papilloma virus vaccines had been reported to the Medicines and Healthcare products Regulatory Agency (MHRA) as at 3 June, and the response by the MHRA to a freedom of information request on 25 June that 2,617 such reactions had been reported as at 24 June, what assessment they have made of the increase in reports over the course of one month.

Answered on

20 July 2015

My Answer of 16 June (HL229) confirmed a total of 2,598 serious suspected adverse reaction reports with human papilloma virus (HPV) vaccines had been reported via the Yellow Card Scheme up to 3 June 2015.

In relation to the additional serious suspected adverse reaction reports received since 3 June 2015, this number is in line with the average number of such reports received per month since the start of the United Kingdom HPV vaccination program.

The safety of all vaccines, including HPV, remains under continual review and appropriate action will be taken if any important new risks are confirmed.

Answered by

Department of Health and Social Care